|
|
|
| Serum MMP9 expression and prognostic value in patients with acute myocardial infarction |
| WANG Luqing, JIANG Hua, MA Xunkai |
| Department of Cardiology , Qinghai Red Cross Hospital, Xining 810000, China |
|
|
|
|
Abstract Objective To investigate the expression of matrix metalloproteinase 9 (MMP9) in the serum of patients with acute myocardial infarction and its prognostic value.Methods Sixty-eight patients with acute myocardial infarction treated with direct coronary intervention in our hospital were selected as the observation group while another 68 healthy volunteers served as the control group. The levels of MMP9 in both groups were detected by ELISA. The patients in the observation group were divided into two groups according to MMP9 levels, with 47 cases in the high MMP9 group and 21 cases in the low MMP9 group, and the incidence of adverse cardiovascular events during follow up was compared between the two groups.Results The serum MMP9 level was (130.93±45.07) μg /L in the control group, much higher than (252.39±82.20) μg /L in the observation group (P<0.05). Logistic regression analysis results showed that MMP9 was one of the independent risk factors for AMI (OR=1.837, P<0.05). ROC analysis results showed that the AUC for MMP9 to predict AMI was 0.901, the optimal operation point was 200.06 μg /L, and the sensitivity and specificity were 0.750 and 0.941 respectively. According to the optimal operation point, patients in the observation group were divided into the high MMP9 group (n=47) and the low MMP9 group (n=21). The rate of adverse cardiovascular events at 6 months, 12 months, 18 months and 24 months after surgery was higher in the high MMP9 group than in the low MMP9 group,especially at 18 months and 24 months after surgery (P<0.05).Conclusions Serum MMP9 is highly expressed in patients with acute myocardial infarction, and MMP9 can be used as a prognostic indicator.
|
|
Received: 20 May 2019
|
|
|
|
|
|
| [1] |
Kuliczkowski W,Urbaniak J,Hallén J,et al. Matrix metalloproteinases and the activity of their tissue inhibitors in patients with ST-eleva-tionmyocardial infarction treated with primary angioplasty [J]. Kardiol Pol,2013,71(5) : 453-463.
|
| [2] |
丁 琪,张金红,王运平,等.急性心肌梗死血栓调节蛋白改变与超敏肌钙蛋白T的相关性[J].武警医学,2017,28(4):364-365.
|
| [3] |
徐晨凯,刘小伟,唐礼江,等. 急性心肌梗死患者血清白三烯B4和基质金属蛋白酶－9表达的变化及其意义[J]. 临床心血管病杂志, 2015,31(5): 536-538.
|
| [4] |
杨韵宏. 基质金属蛋白酶-9 对冠心病患者介入治疗后心血管不良事件发生的预测价值[J]. 医药论坛杂志,2017,38(1):129-130.
|
| [5] |
Gershlick A H,Khan J N,Kelly D J,et al.Randomized trial of com plete versus lesion only revascularization in patients undergoing primary percutaneous coronary intervention for iand multivessel disease: the Cv lprit trial [J]. J Am Coll Cardiol,2015,65(10) : 963-972.
|
| [6] |
刘新宇.基质金属蛋白酶-9、C-反应蛋白及 P 选择素对老年急性心肌梗死患者PCI治疗后效果和预后的评价[J]. 岭南心血管病杂志,2017,23(4) : 381-283.
|
| [7] |
李泽民,梁记华,闫世冉. 心肌梗死患者细胞外基质金属蛋白酶诱导因子表达量与炎性反应、MMPs／TIMPs的相关性[J]. 海南医学院学报,2018, 20(4):1791-1795.
|
| [8] |
Ozako Y,Imanishi T,Tanimoto T,et al. Effect of direct renin inhibitor on left ventricular remodeling in patients with primary acute myocardial infarction [J]. Int Heart J,2014,55(1):17-21.
|
| [9] |
刘海宁,孙金玲.急性心肌梗死患者血清内脏脂肪素与基质金属蛋白酶的相关性研究[J]. 中华老年心脑血管病杂志,2018,20(4) :389-391.
|
| [10] |
Vatankulu M A,Bacaksiz A,Sonmez O,et al. Does spironolactone have a dose-dependent effect on left ventricular remodeling in patients with preserved left ventricular function after an acute myocardial infarction [J]. Cardiovasc Ther,2013,31(4):224-229.
|
| [11] |
胡晓辉,孟皓波,张世维.阿托伐他汀对急性冠脉综合征患者血清MMP-9及IL-18的影响[J].武警医学,2014,25(9):905-907.
|
| [12] |
Gostiljac D,Dorevi P B,Djuri D,et al. The importance of defining serum MMP-9 concentration in diabetics as an early marker of the rupture of atheromatous plaque in acute coronary syndrome [J]. Acta Physiol Hung,2011,98 (1):91-97.
|
| [13] |
谭永锦,谭锦业,甄锦焕,等.mi R-133a与MMP-9在急性心肌梗死患者中的表达及其相关性探讨[J]. 心电图杂志, 2018,7 (4) :1-3.
|
| [14] |
张存新,张玉彪,陈俊华,等.急性心肌梗死34例误诊原因分析[J].武警医学,2018,29(3):305-307.
|
|
|
|
2019, Vol. 30 
